Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex differences in the efficacy of cognitive behavioral therapy for adults with attention-deficit/hyperactivity disorder

  • Crespín, Juan Jesús
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Parramón Puig, Gemma|||0000-0002-6861-7678
  • Biel, Santiago
  • Mestres, Ferran
  • Ramos-Sayalero, Carolina
  • Ibáñez, Pol|||0000-0003-0714-8908
  • Nieva, Gemma|||0000-0003-2630-1218
  • Torrent, Carla|||0000-0003-0335-582X
  • Clougher, Derek|||0000-0001-7631-3845
  • Fadeuilhe, Christian|||0000-0001-5821-347X
  • Amoretti, Silvia|||0000-0001-6017-2734
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
Background and objectives: Cognitive Behavioral Therapy (CBT) is an effective adjunctive treatment for AttentionDeficit/Hyperactivity Disorder (ADHD). This study examined sex differences in the efficacy of a brief 6-session CBT program versus a traditional 12-session format, combined with stable pharmacotherapy, in adults with ADHD. Methods: A total of 81 adults (58 % male; 41.27 ± 9.26 years) were randomly assigned to 6- or 12-session CBT. ADHD symptoms, psychopathology, and functioning were assessed at baseline, post-treatment, and 3- and 6-month follow-up. Mixed-effects models analyzed interactions between time, treatment group, and sex. Results: At baseline, females exhibited greater symptom severity (p = 0.019), higher inattention (p < 0.001), and more pronounced impairments (p = 0.004). CBT led to significant clinical improvements regardless of sex. A significant time-by-sex interaction emerged for inattention (CAARS:O:L, p = 0.043), although it did not remain significant after adjusting for baseline severity. Regarding time × group × sex interactions, females in the 6-session group showed smaller reductions in clinical severity during follow-up (CGI-S, p = 0.047); however, this effect was no longer statistically significant after controlling for baseline ADHD severity. Findings should be interpreted with caution given the limited female sample at follow-up and the significant influence of initial symptom burden on long-term trajectories. Conclusions: CBT improves ADHD symptoms and related impairments in adults, with comparable overall benefits across sexes. Treatment response follow-up differences were better explained by baseline severity and treatment intensity rather than sex-specific differences.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased Disease Burden in Irritable Bowel Syndrome With Comorbid Conditions and Psychiatric Diagnoses in a Multinational European Cohort, Results From the DISCOvERIE Project

  • Midenfjord, Irina|||0000-0003-3168-1075
  • Khadija, Mahrukh
  • Sundelin, Elias|||0000-0001-6485-082X
  • Trindade, Inês A.
  • Tornblom, Hans|||0000-0003-2117-9874
  • Santos, Javier|||0000-0002-4798-5033
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Mulder, Danique|||0000-0002-3927-4784
  • Vasquez, Alejandro Arias
  • Ruesing, Georgy
  • Reif, Andreas|||0000-0002-0992-634X
  • Aichholzer, Mareike|||0000-0002-1291-3304
  • Van Den Houte, Maaike
  • Van Oudenhove, Lukas|||0000-0002-6540-3113
  • Matteucci, Maria Chiara
  • Barbara, Giovanni|||0000-0001-9745-0726
  • Bosman, Michelle|||0000-0002-2040-2520
  • Jonkers, Daisy
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Jekkel, Eva
  • Bitter, István|||0000-0002-9464-4709
  • Pop, Andrei-Vasile
  • Dumitrascu, Dan Lucian
  • Alonso Cotoner, Carmen|||0000-0002-3483-2919
  • Rodríguez-Urrutia, Amanda|||0000-0001-6882-205X
  • Simrén, Magnus
Patients with Irritable bowel syndrome (IBS) frequently suffer from comorbid psychiatric or somatic conditions, but the association with overall GI symptom severity and disease burden in IBS has not yet been established. This pan-European project, the DISCOvERIE project, aimed to characterize IBS patients with and without comorbid psychiatric (anxiety, depression) and/or somatic (fibromyalgia, chronic fatigue syndrome) conditions, and to compare them with disease (psychiatric and/or somatic condition without IBS) and healthy controls to further elucidate the effect of comorbid conditions on the disease burden in IBS. Participants from nine different European centers were included: IBS patients (Rome IV criteria) with and without comorbid conditions, disease controls, and healthy controls. The presence of comorbidities was assessed through the Mini International Neuropsychiatric Interview (MINI) for anxiety or depression or through diagnostic criteria for fibromyalgia or chronic fatigue syndrome. Validated questionnaires on IBS (IBS-SSS), depressive (PHQ-9), anxiety (GAD-7) and somatic symptom severity (PHQ-12), fibromyalgia symptoms (FIQ) and fatigue (MFI) were completed. In total, 842 participants were recruited between March 2021 and January 2023, of which 607 had IBS, 161 were disease controls and 74 were healthy controls. IBS, anxiety, depression, somatic symptoms and fatigue were more severe in IBS patients with comorbidities compared with IBS patients without comorbidities. The severity of the abovementioned symptoms all increased gradually with increasing number of comorbidities (all p.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Does Attention-Deficit/Hyperactivity Disorder Predominant Presentation Matter? Examining Functional and Symptom Changes After Cognitive Behavioural Therapy

  • Crespín, Juan Jesús
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Parramón Puig, Gemma|||0000-0002-6861-7678
  • Querol, Paula
  • Mestres, Ferran
  • Ramos-Sayalero, Carolina
  • Boix, Maria
  • Torrent, Carla|||0000-0003-0335-582X
  • Fadeuilhe, Christian|||0000-0001-5821-347X
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Amoretti, Silvia|||0000-0001-6017-2734
Background: Cognitive behavioural therapy (CBT) is an effective intervention for adults with attention-deficit/hyperactivity disorder (ADHD). While both brief (6-session) and standard (12-session) formats show efficacy, it remains unclear whether treatment response differs between distinct ADHD clinical presentations. Methods: This secondary analysis of a randomized trial included 80 adults with ADHD (57.5% male; mean age = 41.26 ± 9.32 years) allocated to brief or standard CBT. Clinical and functional outcomes were assessed at baseline, posttreatment, as well as 3- and 6-month follow-ups. Linear mixed-effects models and the Reliable Change Index (RCI) evaluated interactions between time, treatment format and ADHD presentation (inattentive vs. combined). Results: CBT yielded significant improvements across all domains, with 94.5% of participants achieving reliable symptomatic improvement. A significant time × presentation interaction (p = 0.001, ηp2 = 0.135) revealed a steeper core symptom reduction in the combined group, which survived sensitivity analyses controlling for baseline severity. Regarding format, the brief version produced greater observer-rated symptom improvement, whereas the standard format yielded greater long-term functional gains (p = 0.009, ηp2 = 0.061). Improvements were sustained at the 6-month follow-up. No robust three-way interactions emerged. Conclusions: CBT is highly effective and durable across ADHD presentations and formats. Although the combined presentation exhibited a more pronounced reduction in core symptoms, this differential trajectory represents a promising clinical trend requiring cautious interpretation. While brief formats efficiently address core symptoms, standard programs may better optimize long-term functional recovery.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan

  • Vilar-Ribó, Laura
  • Cabana-Domínguez, Judit
  • Martorell, Lourdes
  • Ramos-Quiroga, Josep Antoni
  • Sanchez-Roige, Sandra
  • Palmer, Abraham A.
  • Vilella, Elisabet
  • Ribasés, Marta
  • Muntané, Gerard
  • Soler Artigas, María
There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = −0.36, P = 1.41e−16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e−06; Beta = −0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-00444 and 2017SGR-1461), the Instituto de Salud Carlos III (PI18/01788, P19/01224, PI20/00041, PI21/00612, PI22/00464, FI18/00285 to LVR and CP22/00128 to MSA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD); the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014–2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN) and the ECNP Network ‘ADHD across the Lifespan’ and “la Marató de TV3” (202228-30 and 202228-31). SSR was supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226), and NIH/NIDA DP1DA054394. AAP was supported by NIH grant P50DA037844 and R01AA029688 and Tobacco-Related Disease Research Program Grant number: 28IR-0070.
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Mendelian randomization analysis for attention deficit/hyperactivity disorder: studying a broad range of exposures and outcomes

  • Soler Artigas, María
  • Rovira, Paula
Background: Attention deficit/hyperactivity disorder (ADHD) is a highly prevalent neurodevelopmental disorder caused by a combination of genetic and environmental factors and is often thought as an entry point into a negative life trajectory, including risk for comorbid disorders, poor educational achievement or low income. In the present study, we aimed to clarify the causal relationship between ADHD and a comprehensive range of related traits. Methods: We used genome-wide association study (GWAS) summary statistics for ADHD (n¼53 293) and 124 traits related to anthropometry, cognitive function and intelligence, early life exposures, education and employment, lifestyle and environment, longevity, neurological, and psychiatric and mental health or personality and psychosocial factors available in the MR-Base database (16 067 n 766 345). To investigate their causal relationship with ADHD, we used two-sample Mendelian randomization (MR) with a range of sensitivity analyses, and validated MR findings using causal analysis using summary effect estimates (CAUSE), aiming to avoid potential false-positive results. Results: Our findings strengthen previous evidence of a causal effect of ADHD liability on smoking and major depression, and are consistent with a causal effect on odds of decreased average total household income [odds ratio (OR)¼0.966, 95% credible interval (CrI)¼(0.954, 0.979)] and increased lifetime number of sexual partners [OR¼1.023, 95% CrI¼(1.013, 1.033)]. We also found evidence for a causal effect on ADHD for liability of arm predicted mass and weight [OR¼1.452, 95% CrI¼(1.307, 1.614) and OR¼1.430, 95% CrI¼(1.326, 1.539), respectively] and time spent watching television [OR¼1.862, 95% CrI¼(1.545, 2.246)], and evidence for a bidirectional effect for age of first sexual intercourse [beta¼ 0.058, 95% CrI¼( 0.072, 0.044) and OR¼0.413, 95% CrI¼(0.372, 0.457), respectively], odds of decreased age completed full-time education [OR¼0.972, 95% CrI¼(0.962, 0.981) and OR¼0.435, 95% CrI¼(0.356, 0.533), respectively] and years of schooling [beta¼-0.036, 95% CrI¼( 0.048, 0.024) and OR¼0.458, 95% CrI¼(0.411, 0.511), respectively]. Conclusions: Our results may contribute to explain part of the widespread co-occurring traits and comorbid disorders across the lifespan of individuals with ADHD and may open new opportunities for developing preventive strategies for ADHD and for negative ADHD trajectories., European Union H2020 Programme (H2020/2014-2020) 667302 728018 848228 2020604, Instituto de Salud Carlos III European Commission PI18/01788 PI19/00721 P19/01224 PI20/00041 FI18/00285 CD15/00199 CP09/00119 CPII15/00023, Pla estrategic de recerca i innovacio en salut (PERIS), Generalitat de Cata-lunya (METAL-Cat) SLT006/17/287, Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR), Generalitat de Catalunya 2017SGR1461 2016FI_B00899, Ministry of Science, Innovation and Universities IJC2018-035346-I, European Commission, `la Marato' de TV3 092330/31, ECNP Network `ADHD across the Lifespan'
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan

  • Vilar-Ribó, Laura
  • Cabana-Domínguez, Judit
  • Martorell, Lourdes
  • Ramos-Quiroga, Josep Antoni
  • Sanchez-Roige, Sandra
  • Palmer, Abraham A.
  • Vilella, Elisabet
  • Ribasés, Marta
  • Muntané, Gerard
  • Soler Artigas, María
© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = −0.36, P = 1.41e−16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e−06; Beta = −0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-00444 and 2017SGR-1461), the Instituto de Salud Carlos III (PI18/01788, P19/01224, PI20/00041, PI21/00612, PI22/00464, FI18/00285 to LVR and CP22/00128 to MSA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD); the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014–2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN) and the ECNP Network ‘ADHD across the Lifespan’ and “la Marató de TV3” (202228-30 and 202228-31). SSR was supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226), and NIH/NIDA DP1DA054394. AAP was supported by NIH grant P50DA037844 and R01AA029688 and Tobacco-Related Disease Research Program Grant number: 28IR-0070., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan

  • Martorell, Lourdes
  • Sanchez-Roige, Sandra
  • Palmer, Abraham
  • Vilar-Ribo, Laura
  • Cabana-Dominguez, Judit
  • Ribases, Marta
  • Soler Artigas, María
  • Ramos-Quiroga, Josep Antoni
Shared genetic architecture; Attention-deficit and hyperactivity disorder; Lifespan, Arquitectura genética compartida; Trastorno por déficit de atención e hiperactividad; Esperanza de vida, Arquitectura genètica compartida; Trastorn per dèficit d'atenció i hiperactivitat; Esperança de vida, There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = −0.36, P = 1.41e−16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e−06; Beta = −0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-00444 and 2017SGR-1461), the Instituto de Salud Carlos III (PI18/01788, P19/01224, PI20/00041, PI21/00612, PI22/00464, FI18/00285 to LVR and CP22/00128 to MSA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD); the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014–2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN) and the ECNP Network ‘ADHD across the Lifespan’ and “la Marató de TV3” (202228-30 and 202228-31). SSR was supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226), and NIH/NIDA DP1DA054394. AAP was supported by NIH grant P50DA037844 and R01AA029688 and Tobacco-Related Disease Research Program Grant number: 28IR-0070.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan

  • Vilar-Ribó, Laura
  • Cabana-Domínguez, Judit
  • Martorell, Lourdes
  • Ramos-Quiroga, Josep Antoni
  • Sanchez-Roige, Sandra
  • Palmer, Abraham A.
  • Vilella, Elisabet
  • Ribasés, Marta
  • Muntané, Gerard
  • Soler Artigas, María
There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = −0.36, P = 1.41e−16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e−06; Beta = −0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-00444 and 2017SGR-1461), the Instituto de Salud Carlos III (PI18/01788, P19/01224, PI20/00041, PI21/00612, PI22/00464, FI18/00285 to LVR and CP22/00128 to MSA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD); the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014–2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN) and the ECNP Network ‘ADHD across the Lifespan’ and “la Marató de TV3” (202228-30 and 202228-31). SSR was supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226), and NIH/NIDA DP1DA054394. AAP was supported by NIH grant P50DA037844 and R01AA029688 and Tobacco-Related Disease Research Program Grant number: 28IR-0070.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • hartman, catharina
  • Larsson, Henrik
  • Ribases, Marta
  • Mitjans, Marina
  • Soler Artigas, María
  • Demontis, Ditte
  • Ramos-Quiroga, Josep Antoni
Trastorno por déficit de atención e hiperactividad; Comorbilidad; Genética de trastornos cruzados, Trastorn per dèficit d'atenció i hiperactivitat; Comorbiditat; Genètica de trastorns creuats, Attention-deficit/hyperactivity disorder; Comorbidity; Cross-disorder genetics, Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable., This research has received funding from the EU’s Horizon 2020 research and innovation program under grant agreements no. 667302 (CoCA), 728018 (Eat2beNICE) and 2020604 (TIMESPAN) and from the ECNP Network ‘ADHD across the Lifespan' (https://www.ecnp.eu/researchinnovation/ECNP-networks/List-ECNP-Networks/). B Cormand has also been supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-1277760B-I100), the Ministerio de Sanidad, Servicios Sociales e Igualdad/Plan Nacional Sobre Drogas (PNSD-2017I050), Fundació La Marató de TV3 (202218-31), Generalitat de Catalunya/AGAUR (2021-SGR-1093), ICREA Academia 2021 and the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 841899 (GRASAD) and 101028810 (ATTENTIVE). M Ribasés was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE), by the Instituto de Salud Carlos III (PI20/00041, CP09/00119 and CPII15/00023), by the Pla estratègic de recerca i innovació en salut (PERIS), Generalitat de Catalunya (METAL-Cat; SLT006/17/287), by the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461) and by Fundació La Marató de TV3 (202228-30, 202228-31). JA Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE). M Mitjans was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD), the MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR” (RYC2021-033573-I), Ministerio de Ciencia e Innovación (PID2022-139740OA-100) and the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2021-SGR-1093). M Soler Artigas was supported by the Instituto de Salud Carlos III (P19/01224, PI22/00464 and CP22/00128) and by the European Regional Development Fund. B Franke and A Reif were also supported by funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME). B Franke also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the GUTS project (grant 024.005.011). D Demontis is supported by the Novo Nordisk Foundation (NNF20OC0065561 and NNF21SA0072102), the Lundbeck Foundation (R344-2020-1060), the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 965381 (TIMESPAN). AD Børglum was supported by the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003). Research reported in this publication was also supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content of the publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any of the other funding organisations mentioned here.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transcriptomic risk scores for attention deficit/hyperactivity disorder

  • Arribas, Lorena
  • Demontis, Ditte
  • Cabana-Dominguez, Judit
  • Llonga, Natalia
  • Alemany, Silvia
  • Vilar-Ribo, Laura
  • Fadeuilhe, Christian
  • Corrales, Montserrat
  • Richarte, Vanesa
  • Soler Artigas, María
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Transcriptomic risk scores; Attention deficit and hyperactivity disorder, Puntuaciones de riesgo transcriptómico; Trastorno por déficit de atención e hiperactividad, Puntuació de risc transcriptòmic; Trastorn per dèficit d'atenció i hiperactivitat, Attention deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder. We performed a transcriptome-wide association study (TWAS) using the latest genome-wide association study (GWAS) meta-analysis, in 38,691 individuals with ADHD and 186,843 controls, and 14 gene-expression reference panels across multiple brain tissues and whole blood. Based on TWAS results, we selected subsets of genes and constructed transcriptomic risk scores (TRSs) for the disorder in peripheral blood mononuclear cells of individuals with ADHD and controls. We found evidence of association between ADHD and TRSs constructed using expression profiles from multiple brain areas, with individuals with ADHD carrying a higher burden of TRSs than controls. TRSs were uncorrelated with the polygenic risk score (PRS) for ADHD and, in combination with PRS, improved significantly the proportion of variance explained over the PRS-only model. These results support the complementary predictive potential of genetic and transcriptomic profiles in blood and underscore the potential utility of gene expression for risk prediction and deeper insight in molecular mechanisms underlying ADHD., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840), the Instituto de Salud Carlos III and co-funded by the European Union Found: Fondo Social Europeo Plus (FSE+) (P19/01224, PI20/00041, PI22/00464 and FI18/00285 to LVR, CP22/00128 to MSA and CP22/00026 to SA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD), the Network Center for Biomedical Research (CIBER) to JCD, the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN), the ECNP Network ‘ADHD across the Lifespan’ and the “la Marató de TV3” (202228-30 and 202228-31). ADB was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003) and NIH/NIMH (1R01MH124851-01). DD was supported by the Novo Nordisk Foundation (NNF20OC0065561) and the Lundbeck Foundation (R344-2020-1060).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Disentangling heterogeneity in substance use disorder: Insights from genome-wide polygenic scores

  • GRAU-LÓPEZ, LARA
  • Daigre, Constanza
  • Cabana-Dominguez, Judit
  • Soler Artigas, María
  • Alemany, Silvia
  • Llonga, Natalia
  • Vilar-Ribo, Laura
  • Arribas, Lorena
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Heterogeneity; Substance use disorder; Genome, Heterogeneidad; Trastorno por consumo de sustancias; Genoma, Heterogeneïtat; Trastorn per consum de substàncies; Genoma, Substance use disorder (SUD) is a global health problem with a significant impact on individuals and society. The presentation of SUD is diverse, involving various substances, ages at onset, comorbid conditions, and disease trajectories. Current treatments for SUD struggle to address this heterogeneity, resulting in high relapse rates. SUD often co-occurs with other psychiatric and mental health-related conditions that contribute to the heterogeneity of the disorder and predispose to adverse disease trajectories. Family and genetic studies highlight the role of genetic and environmental factors in the course of SUD, and point to a shared genetic liability between SUDs and comorbid psychopathology. In this study, we aimed to disentangle SUD heterogeneity using a deeply phenotyped SUD cohort and polygenic scores (PGSs) for psychiatric disorders and related traits. We explored associations between PGSs and various SUD-related phenotypes, as well as PGS-environment interactions using information on lifetime emotional, physical, and/or sexual abuse. Our results identify clusters of individuals who exhibit differences in their phenotypic profile and reveal different patterns of associations between SUD-related phenotypes and the genetic liability for mental health-related traits, which may help explain part of the heterogeneity observed in SUD. In our SUD sample, we found associations linking the genetic liability for attention-deficit hyperactivity disorder (ADHD) with lower educational attainment, the genetic liability for post-traumatic stress disorder (PTSD) with higher rates of unemployment, the genetic liability for educational attainment with lower rates of criminal records and unemployment, and the genetic liability for well-being with lower rates of outpatient treatments and fewer problems related to family and social relationships. We also found evidence of PGS-environment interactions showing that genetic liability for suicide attempts worsened the psychiatric status in SUD individuals with a history of emotional physical and/or sexual abuse. Collectively, these data contribute to a better understanding of the role of genetic liability for mental health-related conditions and adverse life experiences in SUD heterogeneity., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840 and 2021-SGR-01093), the Instituto de Salud Carlos III (P19/01224, PI20/00041, PI22/00464, PI23/00404 and FI18/00285 to L.V.R, CP22/00128 to M.S.A and CP22/00026 to S.A), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to M.S.A, RYC2021-031324-I to J.C.D and PID2021-1277760B-I100 to B.C. and N.F-C.), the Ministry of Health, Social Services and Equality (PNSD-2020I042 to N.F-C.), the Network Center for Biomedical Research (CIBER) to J.C.D., the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN), the ECNP Network ‘ADHD across the Lifespan’, “Fundació La Marató de TV3” (202228-30, 202228-31 and 202218-31) and ICREA Academia 2021.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Sex differences in the efficacy of cognitive behavioral therapy for adults with attention-deficit/hyperactivity disorder

  • Biel, Santiago
  • Mestres-Ferrés, Ferran
  • Ramos Sayalero, Carolina
  • Fadeuilhe, Christian
  • Crespín Hombrao, Juan Jesús
  • Corrales, Montserrat
  • Richarte, Vanesa
  • Parramon Puig, Gemma
  • Ibáñez-Jiménez, Pol
  • Nieva, Gemma
  • Amoretti, Silvia
  • Ramos-Quiroga, Josep Antoni
ADHD; Cognitive behavioral therapy; Sex differences, TDAH; Teràpia cognitivo-conductual; Diferències sexuals, TDAH; Terapia cognitivo-conductual; Diferencias sexuals, Background and objectives Cognitive Behavioral Therapy (CBT) is an effective adjunctive treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). This study examined sex differences in the efficacy of a brief 6-session CBT program versus a traditional 12-session format, combined with stable pharmacotherapy, in adults with ADHD. Methods A total of 81 adults (58 % male; 41.27 ± 9.26 years) were randomly assigned to 6- or 12-session CBT. ADHD symptoms, psychopathology, and functioning were assessed at baseline, post-treatment, and 3- and 6-month follow-up. Mixed-effects models analyzed interactions between time, treatment group, and sex. Results At baseline, females exhibited greater symptom severity (p = 0.019), higher inattention (p < 0.001), and more pronounced impairments (p = 0.004). CBT led to significant clinical improvements regardless of sex. A significant time-by-sex interaction emerged for inattention (CAARS:O:L, p = 0.043), although it did not remain significant after adjusting for baseline severity. Regarding time × group × sex interactions, females in the 6-session group showed smaller reductions in clinical severity during follow-up (CGI-S, p = 0.047); however, this effect was no longer statistically significant after controlling for baseline ADHD severity. Findings should be interpreted with caution given the limited female sample at follow-up and the significant influence of initial symptom burden on long-term trajectories. Conclusions CBT improves ADHD symptoms and related impairments in adults, with comparable overall benefits across sexes. Treatment response follow-up differences were better explained by baseline severity and treatment intensity rather than sex-specific differences., This research was supported by the Generalitat de Catalunya, Departament de Recerca i Universitats, through the Comissionat per a Universitats i Recerca (SGR grant 2021 SGR 00840). Dr. Amoretti (PI24/00671) and Dr. Torrent (PI20/00344; PI24/00407) thank the support of the Spanish Ministry of Innovation and Science, funded by the Instituto de Salud Carlos III and cofinanced by the European Union (FEDER) “Una manera de hacer Europa”. Dr. Amoretti has been supported by Sara Borrell doctoral programme (CD20/00177) and M-AES mobility fellowship (MV22/00002), from the Instituto de Salud Carlos III (ISCIII), and co-funded by European Social Fund “Investing in your future” and La Marató-TV3 Foundation grants 202234-32. Dr. Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comprehensive analysis of omics data identifies relevant gene networks for Attention-Deficit/Hyperactivity Disorder (ADHD)

  • Cabana-Domínguez, Judit|||0000-0002-4732-7284
  • Soler Artigas, María|||0000-0002-3213-1107
  • Arribas, Lorena|||0000-0002-9683-9999
  • Alemany Sierra, Silvia|||0000-0002-7925-6767
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Llonga, Natalia|||0000-0003-4325-6201
  • Fadeuilhe, Christian|||0000-0001-5821-347X
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent neurodevelopmental disorder that results from the interaction of both genetic and environmental risk factors. Genome-wide association studies have started to identify multiple genetic risk loci associated with ADHD, however, the exact causal genes and biological mechanisms remain largely unknown. We performed a multi-step analysis to identify and characterize modules of co-expressed genes associated with ADHD using data from peripheral blood mononuclear cells of 270 ADHD cases and 279 controls. We identified seven ADHD-associated modules of co-expressed genes, some of them enriched in both genetic and epigenetic signatures for ADHD and in biological pathways relevant for psychiatric disorders, such as the regulation of gene expression, epigenetics and immune system. In addition, for some of the modules, we found evidence of potential regulatory mechanisms, including microRNAs and common genetic variants. In conclusion, our results point to promising genes and pathways for ADHD, supporting the use of peripheral blood to assess gene expression signatures in psychiatric disorders. Furthermore, they highlight that the combination of multi-omics signals provides deeper and broader insights into the biological mechanisms underlying ADHD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mucosal Plasma Cell Activation and Proximity to Nerve Fibres Are Associated with Glycocalyx Reduction in Diarrhoea-Predominant Irritable Bowel Syndrome, Jejunal Barrier Alterations Underlying Clinical Manifestations

  • Pardo-Camacho, Cristina
  • Ganda Mall, John-Peter|||0000-0002-2120-7743
  • Martínez, Cristina|||0000-0002-9368-1356
  • Pigrau Pastor, Marc|||0000-0001-6801-3017
  • Expósito, Elba|||0000-0001-6088-3149
  • Albert-Bayo, Mercé|||0000-0002-9726-8083
  • Melón-Ardanaz, Elisa
  • Nieto Ruiz, Adoración|||0000-0002-3421-2840
  • Rodiño-Janeiro, Bruno
  • Fortea, Marina|||0000-0001-8885-7495
  • Guagnozzi, Danila|||0000-0002-6171-1901
  • Rodríguez-Urrutia, Amanda|||0000-0001-6882-205X
  • de Torres, Inés|||0000-0002-5495-9140
  • Santos-Briones, Ignacio
  • Azpiroz Vidaur, Fernando|||0000-0002-7327-960X
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Alonso Cotoner, Carmen|||0000-0002-3483-2919
  • Santos, Javier|||0000-0002-4798-5033
  • González Castro, Ana Maria|||0000-0003-3955-3318
  • Vicario Perez, Maria|||0000-0001-9622-3185
Irritable bowel syndrome (IBS) is a disorder of brain-gut interaction characterised by abdominal pain and changes in bowel habits. In the diarrhoea subtype (IBS-D), altered epithelial barrier and mucosal immune activation are associated with clinical manifestations. We aimed to further evaluate plasma cells and epithelial integrity to gain understanding of IBS-D pathophysiology. One mucosal jejunal biopsy and one stool sample were obtained from healthy controls and IBS-D patients. Gastrointestinal symptoms, stress, and depression scores were recorded. In the jejunal mucosa, RNAseq and gene set enrichment analyses were performed. A morphometric analysis by electron microscopy quantified plasma cell activation and proximity to enteric nerves and glycocalyx thickness. Immunoglobulins concentration was assessed in the stool. IBS-D patients showed differential expression of humoral pathways compared to controls. Activation and proximity of plasma cells to nerves and IgG concentration were also higher in IBS-D. Glycocalyx thickness was lower in IBS-D compared to controls, and this reduction correlated with plasma cell activation, proximity to nerves, and clinical symptoms. These results support humoral activity and loss of epithelial integrity as important contributors to gut dysfunction and clinical manifestations in IBS-D. Additional studies are needed to identify the triggers of these alterations to better define IBS-D pathophysiology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Present and Future Therapeutic Approaches to Barrier Dysfunction

  • Fortea, Marina|||0000-0001-8885-7495
  • Albert-Bayo, Mercé|||0000-0002-9726-8083
  • Abril-Gil, Mar|||0000-0003-0318-6755
  • Ganda Mall, John-Peter|||0000-0002-2120-7743
  • Serra Ruiz, Xavier|||0000-0003-2478-8923
  • Henao-Paez, Alejandro|||0000-0001-6062-4753
  • Expósito, Elba|||0000-0001-6088-3149
  • González Castro, Ana Maria|||0000-0003-3955-3318
  • Guagnozzi, Danila|||0000-0002-6171-1901
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Alonso Cotoner, Carmen|||0000-0002-3483-2919
  • Santos, Javier|||0000-0002-4798-5033
There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Mitjans, M.
  • Hartman, CA.
  • Artigas, M. Soler
  • Demontis, Ditte|||0000-0001-9124-2766
  • Larsson, Henrik
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Kuntsi, J.
  • Faraone, Stephen V.|||0000-0002-9217-3982
  • Børglum, AD.
  • Reif, Andreas|||0000-0002-0992-634X
  • Franke, Barbara|||0000-0003-4375-6572
  • Cormand, Bru|||0000-0001-5318-4382
Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Transcriptomic risk scores for attention deficit/hyperactivity disorder

  • Cabana-Domínguez, Judit|||0000-0002-4732-7284
  • Llonga, Natalia|||0000-0003-4325-6201
  • Arribas, Lorena|||0000-0002-9683-9999
  • Alemany Sierra, Silvia|||0000-0002-7925-6767
  • Vilar-Ribó, L.|||0000-0001-8758-523X
  • Demontis, Ditte|||0000-0001-9124-2766
  • Fadeuilhe, Christian|||0000-0001-5821-347X
  • Corrales, Montserrat|||0000-0002-7428-1402
  • Richarte, Vanesa|||0000-0001-7327-318X
  • Børglum, Anders D.|||0000-0001-8627-7219
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Soler Artigas, María|||0000-0002-3213-1107
  • Ribasés Haro, Marta|||0000-0003-1039-1116
Attention deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder. We performed a transcriptome-wide association study (TWAS) using the latest genome-wide association study (GWAS) meta-analysis, in 38,691 individuals with ADHD and 186,843 controls, and 14 gene-expression reference panels across multiple brain tissues and whole blood. Based on TWAS results, we selected subsets of genes and constructed transcriptomic risk scores (TRSs) for the disorder in peripheral blood mononuclear cells of individuals with ADHD and controls. We found evidence of association between ADHD and TRSs constructed using expression profiles from multiple brain areas, with individuals with ADHD carrying a higher burden of TRSs than controls. TRSs were uncorrelated with the polygenic risk score (PRS) for ADHD and, in combination with PRS, improved significantly the proportion of variance explained over the PRS-only model. These results support the complementary predictive potential of genetic and transcriptomic profiles in blood and underscore the potential utility of gene expression for risk prediction and deeper insight in molecular mechanisms underlying ADHD.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • hartman, catharina
  • Larsson, Henrik
  • Ribases, Marta
  • Mitjans, Marina
  • Soler Artigas, María
  • Demontis, Ditte
  • Ramos-Quiroga, Josep Antoni
Trastorno por déficit de atención e hiperactividad; Comorbilidad; Genética de trastornos cruzados, Trastorn per dèficit d'atenció i hiperactivitat; Comorbiditat; Genètica de trastorns creuats, Attention-deficit/hyperactivity disorder; Comorbidity; Cross-disorder genetics, Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable., This research has received funding from the EU’s Horizon 2020 research and innovation program under grant agreements no. 667302 (CoCA), 728018 (Eat2beNICE) and 2020604 (TIMESPAN) and from the ECNP Network ‘ADHD across the Lifespan' (https://www.ecnp.eu/researchinnovation/ECNP-networks/List-ECNP-Networks/). B Cormand has also been supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-1277760B-I100), the Ministerio de Sanidad, Servicios Sociales e Igualdad/Plan Nacional Sobre Drogas (PNSD-2017I050), Fundació La Marató de TV3 (202218-31), Generalitat de Catalunya/AGAUR (2021-SGR-1093), ICREA Academia 2021 and the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 841899 (GRASAD) and 101028810 (ATTENTIVE). M Ribasés was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE), by the Instituto de Salud Carlos III (PI20/00041, CP09/00119 and CPII15/00023), by the Pla estratègic de recerca i innovació en salut (PERIS), Generalitat de Catalunya (METAL-Cat; SLT006/17/287), by the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461) and by Fundació La Marató de TV3 (202228-30, 202228-31). JA Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE). M Mitjans was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD), the MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR” (RYC2021-033573-I), Ministerio de Ciencia e Innovación (PID2022-139740OA-100) and the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2021-SGR-1093). M Soler Artigas was supported by the Instituto de Salud Carlos III (P19/01224, PI22/00464 and CP22/00128) and by the European Regional Development Fund. B Franke and A Reif were also supported by funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME). B Franke also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the GUTS project (grant 024.005.011). D Demontis is supported by the Novo Nordisk Foundation (NNF20OC0065561 and NNF21SA0072102), the Lundbeck Foundation (R344-2020-1060), the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 965381 (TIMESPAN). AD Børglum was supported by the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003). Research reported in this publication was also supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content of the publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any of the other funding organisations mentioned here.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Sex differences in the efficacy of cognitive behavioral therapy for adults with attention-deficit/hyperactivity disorder

  • Biel, Santiago
  • Mestres-Ferrés, Ferran
  • Ramos Sayalero, Carolina
  • Fadeuilhe, Christian
  • Crespín Hombrao, Juan Jesús
  • Corrales, Montserrat
  • Richarte, Vanesa
  • Parramon Puig, Gemma
  • Ibáñez-Jiménez, Pol
  • Nieva, Gemma
  • Amoretti, Silvia
  • Ramos-Quiroga, Josep Antoni
ADHD; Cognitive behavioral therapy; Sex differences, TDAH; Teràpia cognitivo-conductual; Diferències sexuals, TDAH; Terapia cognitivo-conductual; Diferencias sexuals, Background and objectives Cognitive Behavioral Therapy (CBT) is an effective adjunctive treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). This study examined sex differences in the efficacy of a brief 6-session CBT program versus a traditional 12-session format, combined with stable pharmacotherapy, in adults with ADHD. Methods A total of 81 adults (58 % male; 41.27 ± 9.26 years) were randomly assigned to 6- or 12-session CBT. ADHD symptoms, psychopathology, and functioning were assessed at baseline, post-treatment, and 3- and 6-month follow-up. Mixed-effects models analyzed interactions between time, treatment group, and sex. Results At baseline, females exhibited greater symptom severity (p = 0.019), higher inattention (p < 0.001), and more pronounced impairments (p = 0.004). CBT led to significant clinical improvements regardless of sex. A significant time-by-sex interaction emerged for inattention (CAARS:O:L, p = 0.043), although it did not remain significant after adjusting for baseline severity. Regarding time × group × sex interactions, females in the 6-session group showed smaller reductions in clinical severity during follow-up (CGI-S, p = 0.047); however, this effect was no longer statistically significant after controlling for baseline ADHD severity. Findings should be interpreted with caution given the limited female sample at follow-up and the significant influence of initial symptom burden on long-term trajectories. Conclusions CBT improves ADHD symptoms and related impairments in adults, with comparable overall benefits across sexes. Treatment response follow-up differences were better explained by baseline severity and treatment intensity rather than sex-specific differences., This research was supported by the Generalitat de Catalunya, Departament de Recerca i Universitats, through the Comissionat per a Universitats i Recerca (SGR grant 2021 SGR 00840). Dr. Amoretti (PI24/00671) and Dr. Torrent (PI20/00344; PI24/00407) thank the support of the Spanish Ministry of Innovation and Science, funded by the Instituto de Salud Carlos III and cofinanced by the European Union (FEDER) “Una manera de hacer Europa”. Dr. Amoretti has been supported by Sara Borrell doctoral programme (CD20/00177) and M-AES mobility fellowship (MV22/00002), from the Instituto de Salud Carlos III (ISCIII), and co-funded by European Social Fund “Investing in your future” and La Marató-TV3 Foundation grants 202234-32. Dr. Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Disentangling heterogeneity in substance use disorder: Insights from genome-wide polygenic scores

  • GRAU-LÓPEZ, LARA
  • Daigre, Constanza
  • Cabana-Dominguez, Judit
  • Soler Artigas, María
  • Alemany, Silvia
  • Llonga, Natalia
  • Vilar-Ribo, Laura
  • Arribas, Lorena
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Heterogeneity; Substance use disorder; Genome, Heterogeneidad; Trastorno por consumo de sustancias; Genoma, Heterogeneïtat; Trastorn per consum de substàncies; Genoma, Substance use disorder (SUD) is a global health problem with a significant impact on individuals and society. The presentation of SUD is diverse, involving various substances, ages at onset, comorbid conditions, and disease trajectories. Current treatments for SUD struggle to address this heterogeneity, resulting in high relapse rates. SUD often co-occurs with other psychiatric and mental health-related conditions that contribute to the heterogeneity of the disorder and predispose to adverse disease trajectories. Family and genetic studies highlight the role of genetic and environmental factors in the course of SUD, and point to a shared genetic liability between SUDs and comorbid psychopathology. In this study, we aimed to disentangle SUD heterogeneity using a deeply phenotyped SUD cohort and polygenic scores (PGSs) for psychiatric disorders and related traits. We explored associations between PGSs and various SUD-related phenotypes, as well as PGS-environment interactions using information on lifetime emotional, physical, and/or sexual abuse. Our results identify clusters of individuals who exhibit differences in their phenotypic profile and reveal different patterns of associations between SUD-related phenotypes and the genetic liability for mental health-related traits, which may help explain part of the heterogeneity observed in SUD. In our SUD sample, we found associations linking the genetic liability for attention-deficit hyperactivity disorder (ADHD) with lower educational attainment, the genetic liability for post-traumatic stress disorder (PTSD) with higher rates of unemployment, the genetic liability for educational attainment with lower rates of criminal records and unemployment, and the genetic liability for well-being with lower rates of outpatient treatments and fewer problems related to family and social relationships. We also found evidence of PGS-environment interactions showing that genetic liability for suicide attempts worsened the psychiatric status in SUD individuals with a history of emotional physical and/or sexual abuse. Collectively, these data contribute to a better understanding of the role of genetic liability for mental health-related conditions and adverse life experiences in SUD heterogeneity., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840 and 2021-SGR-01093), the Instituto de Salud Carlos III (P19/01224, PI20/00041, PI22/00464, PI23/00404 and FI18/00285 to L.V.R, CP22/00128 to M.S.A and CP22/00026 to S.A), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to M.S.A, RYC2021-031324-I to J.C.D and PID2021-1277760B-I100 to B.C. and N.F-C.), the Ministry of Health, Social Services and Equality (PNSD-2020I042 to N.F-C.), the Network Center for Biomedical Research (CIBER) to J.C.D., the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN), the ECNP Network ‘ADHD across the Lifespan’, “Fundació La Marató de TV3” (202228-30, 202228-31 and 202218-31) and ICREA Academia 2021.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Transcriptomic risk scores for attention deficit/hyperactivity disorder

  • Arribas, Lorena
  • Demontis, Ditte
  • Cabana-Dominguez, Judit
  • Llonga, Natalia
  • Alemany, Silvia
  • Vilar-Ribo, Laura
  • Fadeuilhe, Christian
  • Corrales, Montserrat
  • Richarte, Vanesa
  • Soler Artigas, María
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Transcriptomic risk scores; Attention deficit and hyperactivity disorder, Puntuaciones de riesgo transcriptómico; Trastorno por déficit de atención e hiperactividad, Puntuació de risc transcriptòmic; Trastorn per dèficit d'atenció i hiperactivitat, Attention deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder. We performed a transcriptome-wide association study (TWAS) using the latest genome-wide association study (GWAS) meta-analysis, in 38,691 individuals with ADHD and 186,843 controls, and 14 gene-expression reference panels across multiple brain tissues and whole blood. Based on TWAS results, we selected subsets of genes and constructed transcriptomic risk scores (TRSs) for the disorder in peripheral blood mononuclear cells of individuals with ADHD and controls. We found evidence of association between ADHD and TRSs constructed using expression profiles from multiple brain areas, with individuals with ADHD carrying a higher burden of TRSs than controls. TRSs were uncorrelated with the polygenic risk score (PRS) for ADHD and, in combination with PRS, improved significantly the proportion of variance explained over the PRS-only model. These results support the complementary predictive potential of genetic and transcriptomic profiles in blood and underscore the potential utility of gene expression for risk prediction and deeper insight in molecular mechanisms underlying ADHD., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840), the Instituto de Salud Carlos III and co-funded by the European Union Found: Fondo Social Europeo Plus (FSE+) (P19/01224, PI20/00041, PI22/00464 and FI18/00285 to LVR, CP22/00128 to MSA and CP22/00026 to SA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD), the Network Center for Biomedical Research (CIBER) to JCD, the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN), the ECNP Network ‘ADHD across the Lifespan’ and the “la Marató de TV3” (202228-30 and 202228-31). ADB was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003) and NIH/NIMH (1R01MH124851-01). DD was supported by the Novo Nordisk Foundation (NNF20OC0065561) and the Lundbeck Foundation (R344-2020-1060).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan

  • Martorell, Lourdes
  • Sanchez-Roige, Sandra
  • Palmer, Abraham
  • Vilar-Ribo, Laura
  • Cabana-Dominguez, Judit
  • Ribases, Marta
  • Soler Artigas, María
  • Ramos-Quiroga, Josep Antoni
Shared genetic architecture; Attention-deficit and hyperactivity disorder; Lifespan, Arquitectura genética compartida; Trastorno por déficit de atención e hiperactividad; Esperanza de vida, Arquitectura genètica compartida; Trastorn per dèficit d'atenció i hiperactivitat; Esperança de vida, There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = −0.36, P = 1.41e−16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e−06; Beta = −0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-00444 and 2017SGR-1461), the Instituto de Salud Carlos III (PI18/01788, P19/01224, PI20/00041, PI21/00612, PI22/00464, FI18/00285 to LVR and CP22/00128 to MSA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD); the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014–2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN) and the ECNP Network ‘ADHD across the Lifespan’ and “la Marató de TV3” (202228-30 and 202228-31). SSR was supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226), and NIH/NIDA DP1DA054394. AAP was supported by NIH grant P50DA037844 and R01AA029688 and Tobacco-Related Disease Research Program Grant number: 28IR-0070.